Recent 8-K filings for NEOG

• August 7, 2026, 4:02 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

  Neogen director Thierry Bernard resigns from board on Aug 3, 2026

  Thierry Bernard resigned from Neogen Corporation's Board of Directors effective August 3, 2026.

• July 30, 2026, 7:01 AM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Neogen reports Q4 FY2026 revenue $225.3M, net loss $11.3M; core growth 4.3%

  Q4 revenue $225.3M (flat YoY); core growth 4.3%; full-year revenue $870.4M, core growth 1.9%.

• April 20, 2026, 7:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  Neogen completes operational qualifications for Petrifilm SKUs; moves to performance qualifications

  Successfully completed multiple operational qualifications for certain Petrifilm single kit units (SKUs).

• April 9, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  Neogen Q3 FY26 revenue $211.2M; net loss $17M; divests Genomics unit

  Revenue $211.2M; Food Safety core growth +4.0%, Animal Safety core growth –8.7% on supplier challenges.

• March 30, 2026, 7:59 PM ET leadership materiality 0.55 negative item 5.02

  Neogen's Chief Legal and Administrative Officer Amy Rocklin to depart March 31, 2026

  Amy Rocklin, Chief Legal and Administrative Officer, is leaving Neogen effective March 31, 2026.

• January 8, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Neogen Q2 revenue $224.7M (-2.8% YoY); core growth +2.9%; raises FY guidance

  Net loss of $15.9M; adjusted net income of $22.6M; adjusted EBITDA of $48.7M.

• October 30, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01

  Neogen appoints Bryan Riggsbee as CFO effective Nov 3, 2025

  Riggsbee named SVP & CFO, succeeding David Naemura who remains through end of 2025 to aid transition.

• October 28, 2025, 7:59 PM ET leadership materiality 0.10 neutral item 5.02item 9.01

  Neogen assigns new director Avi Pelossof to Audit and Compensation Committees

  Avi Pelossof appointed to Audit Committee and Compensation and Talent Management Committees effective October 24, 2025.

• October 27, 2025, 7:59 PM ET other material materiality 0.15 positive item 5.07item 9.01

  Neogen amends 8-K to show shareholders approved executive compensation proposal

  Original 8-K incorrectly reported Proposal 2 (say-on-pay) as not approved; corrected to show approval.

• October 27, 2025, 7:59 PM ET other material materiality 0.15 negative item 5.07item 9.01

  Neogen shareholders reject say-on-pay at 2025 annual meeting

  Directors Thierry L. Bernard, Mikhael Nassif, Avi Pelossof, Andrea F. Wainer elected with >90% support.

• October 9, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Neogen Q1 FY2026 revenue $209.2M, net income $36.3M; new CEO Mike Nassif

  Revenue $209.2M, net income $36.3M; adjusted net income $9.4M, adjusted EBITDA $35.5M.

• September 15, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 8.01item 9.01

  Neogen CFO & COO David Naemura resigns voluntarily; successor search underway

  Naemura will remain CFO/COO until October filing of 10-Q, no later than Dec 31, 2025.

• August 21, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 9.01

  Neogen grants PSUs and stock options to CEO and other NEOs for FY2026 LTI

  CEO Mikhael Nassif receives 414,365 PSUs (target) and 1,065,042 options at $5.43 strike, vesting over 3 years.

• August 14, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01

  Neogen announces board retirement of William Boehm, appointment of Avi Pelossof effective Oct 23/24

  William T. Boehm to retire from Neogen's Board effective Oct 23, 2025; served since 2011, chairs Audit Committee, member of Compensation & Talent Management Committee.

• July 29, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Neogen Q4 FY2025 revenue $225.5M; net loss $612.2M on goodwill impairment; adj. EPS $0.05

  Revenue $225.5M; net loss $612.2M ($2.82 diluted loss) primarily from non-cash goodwill impairment.

• July 24, 2025, 7:59 PM ET leadership materiality 0.70 neutral item 5.02item 8.01item 9.01

  Neogen appoints Mikhael Nassif as President and CEO effective August 11, 2025

  Mikhael Nassif, former Siemens Healthineers Global President of Point-of-Care Diagnostics, appointed CEO.

• June 4, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Neogen furnishes investor presentation at William Blair conference; no specifics in filing

  Neogen presented at the William Blair Growth Stock Conference on June 4, 2025.

• May 14, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Neogen furnishes slides for BofA Healthcare Conference; no material new data provided

  Presentation at 2025 Bank of America Healthcare Conference on May 14.

• May 13, 2025, 7:59 PM ET leadership materiality 0.45 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×2

  Neogen announces board retirement of James P. Tobin, appoints Andrea Wainer effective June 1, 2025

  James P. Tobin retires from Neogen board effective May 31, 2025 after nine years of service.

• April 22, 2025, 7:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Neogen hosts investor meeting on Petrifilm product line

  Investor event held April 22, 2025, in Lansing, MI, focused on Petrifilm.

• April 9, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Neogen Q3 FY2025: revenue $221M, net loss $11M; updates guidance

  Net loss of $11.0M ($0.05 diluted EPS); adjusted net income of $20.9M ($0.10 adjusted EPS).

• April 9, 2025, 7:59 PM ET leadership materiality 0.70 neutral item 5.02item 9.01 ◈ executive_change

  Neogen CEO John Adent to step down; board forms search committee

  John Adent will remain CEO/President until successor appointed; then serve as Special Advisor through Oct 31, 2025.

• April 7, 2025, 7:59 PM ET debt materiality 0.55 positive item 1.01item 2.03item 7.01item 9.01

  Neogen refinances $550M debt: new $450M term loan and $250M revolver at lower rate

  Refinanced $550M of existing term loan and revolver due 2027; new $450M term loan and $250M revolver mature Apr 2030.

• January 10, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Neogen Q2 net loss $456.3M ($2.10/share) on goodwill impairment; adj EPS $0.11

  Revenue $231.3M; net loss $456.3M ($2.10 diluted) primarily from non-cash goodwill impairment.

• January 7, 2025, 6:59 PM ET leadership materiality 0.45 neutral item 5.02item 9.01 ◈ executive_change ×2

  Neogen appoints David Naemura as COO alongside CFO; Doug Jones retiring Feb 28, 2025

  David Naemura appointed COO effective Jan 1, 2025, retaining CFO role.

• December 17, 2024, 6:59 PM ET leadership materiality 0.25 neutral item 5.02item 9.01

  Neogen adds committee assignments for director Thierry Bernard

  Amends prior 8-K to disclose committee roles for newly appointed director Thierry Bernard.

• December 4, 2024, 6:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Neogen posts investor presentation for Piper Sandler Healthcare Conference

  Neogen filed an 8-K on December 4, 2024, regarding its presentation at the 2024 Piper Sandler Healthcare Conference.

• October 28, 2024, 7:59 PM ET other material materiality 0.15 negative item 5.07item 9.01

  Neogen shareholders reject say-on-pay at 2024 annual meeting

  Say-on-pay vote failed: 96,518,858 for vs. 101,431,438 against, 677,525 abstain.

• October 10, 2024, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Neogen Q1 net loss $12.6M; revenue down 5.3% YoY; guidance unchanged

  Revenue $217.0M, down 5.3% YoY; core revenue declined 1.4%; currency headwind 3.9%.

• October 10, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01 ◈ executive_change

  Neogen COO Douglas E. Jones to retire early 2025; commercial role added

  COO Douglas E. Jones plans retirement in early 2025; will facilitate transition of duties.

• October 1, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  Neogen appoints QIAGEN CEO Thierry Bernard to board of directors

  Thierry Bernard appointed to Neogen Board of Directors, effective November 1, 2024.

• September 5, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Neogen furnishes investor presentation for Wells Fargo Healthcare Conference

  Presentation dated September 5, 2024, published for the 2024 Wells Fargo Healthcare Conference.

• July 30, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Neogen Q4 revenue $236.8M down 2.1% YoY; net loss $0.02 EPS; guides FY25 rev $925-955M

  Revenue $236.8M, down 2.1% YoY; core revenue grew 2.0% as FX headwind of 4.2% offset.

• June 4, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Neogen furnishes investor presentation for William Blair Growth Stock Conference

  Presentation materials published on June 4, 2024 for William Blair Growth Stock Conference.

• April 9, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Neogen reports Q3 revenue up 4.8% to $228.8M but net loss of $2.0M; cuts FY2024 outlook

  Net loss of $2.0M ($0.01 diluted EPS) vs net income $8.2M ($0.04) a year ago.

• April 5, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01 ◈ executive_change ×2

  Neogen appoints John Moylan as VP, Corporate Controller and CAO

  John Moylan appointed VP, Corporate Controller, and Chief Accounting Officer effective April 15, 2024.

• January 9, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Neogen Q2 FY2024 revenue $229.6M, net loss $(0.02)/sh; lowers full-year outlook

  Revenue $229.6M, roughly flat YoY; Food Safety +1.9%, Animal Safety -5.0%.

• October 31, 2023, 7:59 PM ET other material materiality 0.60 neutral item 5.02item 5.03item 5.07item 9.01 ◈ Shareholder Votes ×5◈ Governance Changes

  Neogen enters new severance agreements, amends bylaws, and holds annual meeting

  New severance letters for CEO Adent, CFO Naemura, and other NEOs; 2x salary for CEO, 1x for others on non-Cause/Good Reason termination.

• October 10, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neogen Q1 FY2024 revenue $229M (+73%); core revenue declines 1.3%; adj. EPS $0.11

  Revenue $229.0M, +73% YoY driven by 3M Food Safety acquisition; core revenue ex-acquisition declined 1.3%.

• September 7, 2023, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Neogen furnishes investor presentation for 2023 Wells Fargo Healthcare Conference

  Presentation filed as Exhibit 99.1 on September 7, 2023.

• July 27, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Neogen Q4 revenue up 72.6% to $241.8M; net income $5.6M; FY2024 guidance issued

  Q4 revenue $241.8M (+72.6% YoY); net income $5.6M ($0.03 EPS); adjusted net income $30.2M ($0.14 EPS).

• June 6, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Neogen presents at William Blair Growth Stock Conference; no material updates disclosed

  Filed investor presentation dated June 6, 2023 for William Blair conference.

• April 6, 2023, 7:59 PM ET leadership materiality 0.35 neutral item 5.02item 9.01 ◈ executive_change

  Board member Darci Vetter to resign after 2023 annual meeting due to new PepsiCo role

  Darci Vetter resigns from Neogen Board effective day after 2023 annual meeting.

• March 30, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neogen Q3 revenue $218.3M (+70% YoY); adjusted EPS $0.12 vs $0.15 prior year

  Revenue $218.3M (+70% YoY); core growth 4%, acquisition 68.1%, FX -1.9%.

• January 5, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neogen Q2 revenue up 76% to $230M; GAAP net loss $41.8M; adjusted net income $31.4M

  Revenue $230.0M, up 76.2% YoY; core revenue growth (ex-acquisitions & FX) 6.6%.

• November 30, 2022, 6:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  Neogen presents business update at Piper Sandler conference, slides filed but no extractable details

  Business update presented at Piper Sandler 34th Annual Healthcare Conference on November 30, 2022.

• October 7, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Neogen shareholders elect directors, approve say-on-pay and auditor at 2022 annual meeting

  All three director nominees elected: John E. Adent (77.6M votes), William T. Boehm (75.3M), James P. Tobin (73.7M).

• September 28, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Neogen Q1 revenue up 3% to $132.3M; net income down to $0.05/sh due to $13.7M deal costs

  Revenue $132.3M, up 3% (6% constant currency); organic growth 4%.

• September 27, 2022, 7:59 PM ET leadership materiality 0.65 neutral item 5.02item 9.01 ◈ executive_change ×2

  Neogen CFO Steve Quinlan to retire May 2023; David Naemura to succeed as CFO

  CFO Steve Quinlan to retire effective May 31, 2023; has served since 2011.

• September 9, 2022, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change ×2

  Neogen expands board to 10, appoints Capello and Gupta as directors

  Board size increased from 8 to 10 directors on September 2, 2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event leadership

4 positive 11 negative 35 neutral

source · NEOG on sec.gov